Article
KRAS G12R in pancreatic cancer: why this mutation resists current inhibitor strategies.
The oncologist - 6 Jun 2026
Kern Kenneth A
Abstract excerpt
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal solid malignancies, with limited therapeutic progress despite decades of cytotoxic chemotherapy. About 90% of PDAC tumors harbor activating mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS), making oncogenic KRAS signaling a longstanding therapeutic target. Although KRAS G12C inhibitors have demonstrated clinical...
Topics
Join the communities discussing this publication.